In addition to members of MKP subfamily, members of the Protein tyrosine phosphatase type IV subfamily (PTPIV, also known as PRLs) have also been suggested to be potential anti-tumor immunotherapy targets due to their role in carcinogenesis with antibody therapy against PRL proteins inhibiting metastasis in PRL-expressing tumors [21,22]. Here, PRL is linked to neoplasm.